FIG 4.

Probability of SVR12, with 95% confidence limits, in patients with HCV GT-1a (solid lines) or GT-1b (dashed lines) infection according to APRI score (top) or liver elasticity (bottom). The plots are based on a multiple logistic regression model of interaction of SVR12 versus log₁₀(APRI score or Fibroscan), genotype, and genotype by log₁₀(APRI score or Fibroscan) and are limited to ribavirin-containing groups. Genotype by log₁₀(APRI), P = 0.3867; genotype by log₁₀(Fibroscan), P = 0.5041. APRI, aspartate aminotransferase/platelet ratio index; GT, genotype; SVR12, sustained virologic response 12 weeks after completion of treatment.